Table 4.
Immune Activation and Inflammatory Parameters at Baseline and After 8 Weeks of Intervention
| Parameter | Group | Baseline | Wk 8 | Δ (Wk 8 − Baseline) |
P Value |
|
|---|---|---|---|---|---|---|
| Baseline | Δ Between Group | |||||
| CD4+/CD8+ ratio | Placebo | 0.85 ± 0.38 | 0.90 ± 0.35 | 0.05 ± 0.10 | .86 | .65 |
| Sitagliptin | 0.87 ± 0.48 | 0.87 ± 0.51 | 0.00 ± 0.15 | |||
| D-dimer, μg FEU/mL | Placebo | 0.28 ± 0.15 | 0.31 ± 0.20 | 0.03 ± 0.18 | .56 | .78 |
| Sitagliptin | 0.32 ± 0.20 | 0.33 ± 0.24 | 0.01 ± 0.18 | |||
| IL-6, pg/mL | Placebo | 2.61 ± 1.91 | 2.65 ± 1.83 | 0.18 ± 0.64 | 0.02 | 0.24 |
| Sitagliptin | 1.36 ± 0.74 | 1.30 ± 0.55 | −0.06 ± 0.58 | |||
| sCD14, ng/mL | Placebo | 3331 ± 1836 | 2917 ± 1523 | −414 ± 890 | .005 | .05 |
| Sitagliptin | 1899 ± 487 | 2024 ± 656 | 126 ± 668 | |||
| Adipose CCL2 (MCP-1) mRNA | Placebo (n = 7) | −0.4 ± 1.2 fold change | .01 | |||
| Sitagliptin (n = 11) | −2.5 ± 1.9 fold change | |||||
| Adipose EMR1 mRNA | Placebo (n = 6) | −0.7 ± 1.3 fold change | .19 | |||
| Sitagliptin (n = 11) | −1.9 ± 2.3 fold change | |||||
Abbreviations: CXCL10, C-X-C motif chemokine 10 (interferon-γ inducible protein; IP-10); CCL2, chemokine (C-C motif) ligand 2 (MCP-1). FEU, Fibrinogen equivalent units. Data are expressed as mean ± SD.